Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma

BMC Gastroenterology

Table 2 HBcAb positive “only” patients characteristics

		Rituximab containing protocols
Variable	Overall	Yes	No	p
No. of patients	96	48	48	ns
Age - Mean [±SD]	64,39 ± 9,63	65,17 ± 10,21	64,02 ± 8,37	ns
Sex – M/F	M: 57	M: 30	M: 27	ns
Sex – M/F	F: 39	F: 18	F: 21	ns
Lymphoma type	Indolent: 50	Indolent: 17	Indolent: 33	0,001
Lymphoma type	Aggressive: 46	Aggressive: 31	Aggressive: 15	0,001
Probable OBI reactivation	10 [10,42%]	5 [10,42%]	5 [10,42%]	ns
NUC profilaxys/rescue therapy	0/10	0/5	0/5	ns
“Per year Incidence of reactivation” [mean ± SD]	8,23% ± 9,84	9,08% ± 10,69	11,54% ± 40,74	ns
Reactivation time [mean weeks after therapy]	26,67 ± 12,20	31,60 ± 14,50	20,50 ± 4,72	ns
Liver related decompensations/hospitalizations/deaths	0%	0%	0%	-

No statistical differences were found in patients treated with ad without Rituximab. (Chi-square, Pearson corrected calculations for all variables, Age, incidence of reactivation and reactviation time: student t-test).

ISSN: 1471-230X